# A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

> **NCT01674712** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 575 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** Fixed Combination of Fenofibrate/simvastatin 145/20 mg
- **DRUG:** Simvastatin 20 mg
- **DRUG:** Fenofibrate 145 mg
- **DRUG:** Fixed Combination of Fenofibrate/simvastatin 145/40 mg
- **DRUG:** Simvastatin 40 mg

## Key facts

- **NCT ID:** NCT01674712
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 575 (ACTUAL)
- **Last updated:** 2014-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01674712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01674712, "A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01674712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*